Start here if you're new
what it is
It sells HydraFacial machines and refill products to spas, clinics, and aestheticians who sell treatments to your face.
how it gets paid
Last year Beauty Health made $301M in revenue. HydraFacial consumables was the main engine at $135M, or 45% of sales.
why growth slowed
Revenue fell 10.0% last year. 65.3% gross margin mattered most because it shows the product still has pricing power even while the income statement looks like a cleanup job.
what just happened
Beauty Health beat on revenue, with quarterly sales hitting $82.4M, but the business still lost money.
At a glance
C+ balance sheet — struggling to keep the lights on
9.0% return on capital — nothing to write home about
-$0.10 fy2027 eps est
$400M fy2029 rev est
6.9% operating margin
xvary composite: 15/100 — weak
What they do
It sells HydraFacial machines and refill products to spas, clinics, and aestheticians who sell treatments to your face.
The best part of this business is the refill loop. Once a provider buys a HydraFacial machine, your treatment room depends on branded serums, tips, and repeat sessions, and the company still posted a 65.6% gross margin. Gross margin → money left after making the product → so what: the refill economics are better than a one-time box sale.
How they make money
$301M
annual revenue · their business grew -10.0% last year
HydraFacial consumables
$135M
+4.0%
Delivery systems
$90M
24.0%
Skincare and boosters
$53M
6.0%
Service, training, and warranties
$23M
+2.0%
The products that matter
professional skin treatment hardware
Syndeo devices
$105M delivery-systems revenue
Each machine costs more than $30,000, which makes every sale meaningful and every slowdown painful. The problem is the 2023 recall cost at least $63.2M to manage.
recall overhang
recurring treatment supplies
Consumables & serums
$196M · 65.2% of revenue
This is the better business inside the business. It generated $196M last year, and the 35,409-system installed base is what keeps reorders coming.
repeat revenue
provider footprint
Installed base
35,409 systems · +3.6%
This number matters more than most headline metrics. If the installed base keeps growing, consumables can recover faster than device sales. If it stalls, the whole turnaround thesis gets smaller.
key metric
Key numbers
$363M
long-term debt
Debt is almost 3x the market cap, which means your upside depends on survival first and growth second.
6.9%
operating margin
Operating margin → profit after running the business → so what: the core business still loses money before interest pain even starts.
$301M
annual revenue
This is the sales base the company is trying to fix, and it shrank 10.0% vs. prior year.
65.6%
gross margin
Gross margin → money left after making the product → so what: the product economics are decent even if the company economics are not.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $363M (74% of capital)
- net profit margin 10.0% — keeps 10 cents of every dollar in revenue
- return on equity 14% — $0.14 profit for every $1 investors have put in
C+ — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
You invested $10,000 in SKIN 3 years ago → it's now worth $790.
The index would have given you $13,880.
source: institutional data · total return
What just happened
beat estimates
Beauty Health beat on revenue, with quarterly sales hitting $82.4M, but the business still lost money.
Last earnings came in at -$0.09 versus a -$0.11 estimate, a small beat. Gross margin improved to 65.3% for the year, but guidance said first-half 2026 revenue may run below the prior year.
$82.4M
revenue
$0.09
eps
65.3%
gross margin
the number that mattered
65.3% gross margin mattered most because it shows the product still has pricing power even while the income statement looks like a cleanup job.
-
the beauty health company is set to release fourth-quarter results on march 11th.the parent company of hydrafacial likely reported another period of weak device sales in the final stanza. recall, a malfunction with the first two versions of the syndeo machine in november of 2023 forced the company’s hand in replacing customers’ existing devices with the latest version. (we estimate the average lifespan of a machine to be about five years.) moreover, high interest rates and macroeconomic uncertainty are causing spas and clinics to freeze capital expenditures, which bodes ill for the $30,000-plus price tag a new machine costs.
-
nonetheless, data suggests that providers with the device are using them frequently.
-
therefore, consumable sales might have been a bright spot.
-
even still, the company most likely reported another bottom-line loss.consumable sales appear resilient, which could allow the company to register favorable sales comparisons in 2026.
-
demand for the syndeo device is expected to remain soft throughout much of this year, too.nonetheless, the active installed base continued to grow, reaching 35,409 in the september period (up from 34,162 in the comparable quarter a year earlier).
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is Syndeo reliability and recall fallout. A single hardware issue already cost at least $63.2M, and this company does not have room for many mistakes.
high
Syndeo reliability and recall costs
The 2023 recall cost at least $63.2M to manage. For a company with a $125M market cap, that's not a footnote. That's the story.
one product issue consumed more than half of 2025 adjusted EBITDA
high
Debt load versus weak earnings
Long-term debt is $363M, or 74% of capital, while 2025 still ended with a $9.5M net loss. Leverage looks a lot heavier when profitability stays theoretical.
limits flexibility if the recovery slips again
med
Flat 2026 revenue outlook
Guidance of $285M–$305M implies the business could spend another year going sideways. A turnaround stock without visible growth usually stays cheap.
keeps the multiple low even if margins improve
med
Capital spending sensitivity at clinics and spas
Management still needs customers to spend $30,000-plus on new systems. When rates are high and budgets get tight, that purchase is easy to delay.
pressures the $105M delivery-systems segment first, then the refill engine later
A stalled device recovery would hit the $105M hardware business directly and eventually slow the recurring sales tied to a 35,409-system installed base.
source: institutional data · regulatory filings · risk analysis
Pay attention to
earnings
Q1 2026 results
The next report is due March 18, 2026. Management guided to $63M–$68M in revenue. You want to see delivery-systems demand stop deteriorating.
installed base
35,409 needs to keep rising
Installed base growth was 3.6% last year. That's not explosive, but it is the clearest leading indicator for future consumables demand.
balance sheet
Debt versus profit
$363M of long-term debt is manageable only if losses keep narrowing. Another ugly earnings year would make leverage the whole conversation.
street view
Target revisions after guidance
The average analyst target is $1.96, but the range runs from $1.50 to $3.50. That spread tells you conviction is low and the debate is wide open.
Analyst rankings
risk profile
high risk
risk rank 5 — significant risk of large drawdowns.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 36 buyers vs. 30 sellers in 4q2025. total institutional holdings: 76.6M shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$1
$3
$1
current price
$2
target midpoint · +120% from current · 3-5yr high: $5 (+450% · 55% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive